Key result
Olmesartan-based treatments have positive effects on ambulatory blood pressure prognostic indicators, including 24-hour, daytime, and nighttime blood pressure control, morning surge, and blood pressure variability.
Why the study?
Does olmesartan-based antihypertensive therapy improve ambulatory blood pressure indicators in patients with hypertension?
Does olmesartan-based antihypertensive therapy improve ambulatory blood pressure indicators in patients with hypertension?
Answers are grounded in this paper and cite their sources.
Olmesartan-based therapies effectively improve out-of-office blood pressure indicators, which are closely correlated with cardiovascular prognosis.
Ambulatory blood pressure (BP) correlates more significantly with hypertension-associated cardiovascular mortality and morbidity than BP obtained in the doctor's office. Assessing ambulatory BP, either through 24-h monitoring or through protocolized self-measurement at home, is essential in diagnosing and monitoring patients with hypertension. Several ambulatory BP-derived indicators are related with cardiovascular prognosis. These include 24-h, daytime and nighttime BP measurements, BP measurements obtained through home self-measurement, dipping status, morning surge, and BP variability. The objective of this article was to review the effect of olmesartan-based antihypertensive therapy on the main risk variables obtained when assessing ambulatory BP.
No takes yet. Share an insight, caveat, or question.
Manuel Gorostidi (2015) conducted a review in Hypertension. Olmesartan-based therapies was evaluated. Olmesartan-based treatments have positive effects on ambulatory blood pressure prognostic indicators, including 24-hour, daytime, and nighttime blood pressure control, morning surge, and blood pressure variability.
Synapse has enriched 10 related papers. Consider them for comparative context: